


To provide an income greater than that of the FTSE All Share Index together with capital growth over the longer term.
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline | 6.0% |
| AstraZeneca | 4.4% |
| BP | 4.3% |
| Vodafone | 4.3% |
| Royal Dutch Shell | 4.2% |
| Imperial Tobacco | 4.0% |
| Indus Gas | 3.8% |
| KSK Power Ventur | 3.8% |
| Compass Group | 3.4% |
| Reed Elsevier | 3.4% |
| Key | % Net Assets |
|---|---|
| 6.0% | |
| 4.4% | |
| 4.3% | |
| 4.3% | |
| 81% |
| Date | n/a |
|---|---|
| Bid | 0.00 |
| Offer | 0.00 |
| Currency | n/a |
| Change | 0.00 |
| % | n/a |
| YTD change | 0.00 |
| YTD % | n/a |
| Fund Inception | 01/01/1963 |
|---|---|
| Fund Manager | Richard Dunbar |
| TER | 1.63 (31-Dec-2013) |
| Minimum Investment | |
|---|---|
| Initial | 1000 |
| Additional | n/a |
| Savings | 50 |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.13 |
You are here: research